Dr. Meshad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3719 Dauphin Street
5TH floor
Mobile, AL 36608Phone+1 251-625-6896Fax+1 251-625-6897
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1978 - 1980
USA HealthResidency, Internal Medicine, 1975 - 1978
Letterman Army Medical CenterInternship, Transitional Year, 1972 - 1973
University of Alabama School of MedicineClass of 1972
Certifications & Licensure
AL State Medical License 1975 - 2024
MS State Medical License 2009 - 2016
FL State Medical License 2007 - 2011
NC State Medical License 1973 - 1976- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Publications & Presentations
PubMed
- 5 citationsPaclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.Brenda P. Nicholson, David M. Paul, Kenneth R. Hande, Yu Shyr, Michael Meshad
Clinical Breast Cancer. 2000-07-01 - 16 citationsOral Ondansetron 8 mg Twice Daily is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemo...Thomas M. Beck, Martin York, A Y Chang, Rudolph M. Navari, Walter H. Harvey
Cancer Investigation. 1997-01-01 - 14 citationsResults of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.William R. Berry, Karen W. House, Jeffrey T. Lee, Paige B. Plagge, Michael W. Meshad
Seminars in Oncology. 1992-12-01
Press Mentions
- FIGHTING TO WIN: A 28-Year-Old’s Journey Through Colon CancerOctober 20th, 2020
Southern Cancer Center Is Global Leader in Kidney Cancer Clinical TrialSeptember 19th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
